What are the listed companies that produce anticancer drugs?

The Twelfth Five-Year Plan for Biomedicine has determined the key points of biomedical development, including gene drugs, protein drugs, monoclonal antibody drugs, therapeutic vaccines and small molecular chemicals. At the same time, the state will spend more than 654.38 billion yuan to support the creation of major new drugs. The state will select more than 10 new drugs from more than 100 new drugs as the key support objects for major new drug creation. These original new drugs may become pioneers in entering the European and American markets. Among these varieties, biological drugs and chemical drugs are the majority, including vaccines, monoclonal antibodies, protein drugs and anticancer drugs. Anti-cancer drug concept stocks produced by A-shares: 1, Huashen Group (000790): The primary liver cancer drug iodine [13 1I] Metuximab injection (Likadin) owned by the company is a national innovative drug, and it is the first gene drug in the world to treat liver cancer with monoclonal antibodies. The company has independent intellectual property rights for the treatment of advanced liver cancer. 2. Baiyi Pharmaceutical Co., Ltd. (600594): The company owns Aidi injection, a traditional Chinese medicine with genetic technology, and obtains VEGI proprietary technology of polypeptide chain products through genetic engineering, which can directly activate different types of immune cells and inhibit or eliminate cancer cells. 3. Hengrui Pharma (600276): The company's single enantiomer chiral drug, calcium levofolinate, can be used to enhance the anti-tumor activity of 5- fluorouracil, which is mainly used to treat the symptoms related to folic acid antagonism of osteosarcoma, colon cancer and kidney cancer after high-dose methotrexate treatment; The company ranks first in China in a variety of anti-tumor drugs, three of which are exclusively produced in China. The existing generic drugs oxaliplatin and docetaxel are in the growth stage, and irinotecan is also entering a period of rapid growth. The company should have apatinib mesylate, a molecular targeted anti-tumor drug. 4. Yuheng Pharmaceutical Co., Ltd. (002437): Gemcitabine Hydrochloride-Antitumor Drug: Gemcitabine Hydrochloride for Injection is an anti-metabolic tumor drug, which is widely used to treat pancreatic cancer and non-small cell lung cancer. In China, only three pharmaceutical companies, Lilly, Jiangsu Haosen and Yuheng Pharmaceutical, produce 5. Laimei Pharmaceutical Co., Ltd. (300006): The company's core technologies include nano-drug technology for lymphatic targeted therapy, micro-nano dispersed suspension preparation technology for drugs, and sterile raw material preparation technology, among which nano-drug technology for lymphatic targeted therapy is at the international leading level; Anti-tumor drugs are mainly nano-carbon suspension injection and fludarabine phosphate for injection, and parenteral nutrition drugs are mainly N(2)-L- alanyl -L- glutamine injection, which fills the gap in China and has great clinical application value. 6. Tetracyclic Organism (0005 18): The company's main products are recombinant human interleukin-2 (used for comprehensive treatment of malignant tumors such as renal cancer and malignant melanoma), recombinant human granulocyte stimulating factor injection and recombinant human erythropoietin injection, among which recombinant human interleukin-2 for injection is the national project "Genetically engineered human interleukin -2", and Beijing Sihuan Biopharmaceutical, which still holds 55% of the shares, is the earliest one engaged in genetic engineering drugs and diagnosis in China. Its proprietary technology includes sublingual buccal tablets such as interleukin -2 (used to treat liver cancer), interferon, EPO and G-CSF. 7. anke biotechnology Science and Technology (300009): The company plans to introduce anti-tumor drug S- 1 tablet project. S- 1 is a new compound antitumor drug, which is mainly used to treat advanced or metastatic gastric cancer. It is estimated that 20 12 will be put into production, with an annual production capacity of 30 million pieces.